nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—SLC22A2—chronic kidney failure	0.0463	0.053	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Norepinephrine Neurotransmitter Release Cycle—SLC22A2—chronic kidney failure	0.0406	0.0465	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC22A2—chronic kidney failure	0.0388	0.0445	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A13—chronic kidney failure	0.0333	0.0382	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—sympathetic nervous system—chronic kidney failure	0.0296	0.31	CbGeAlD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DDC—chronic kidney failure	0.0288	0.033	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Amine compound SLC transporters—SLC22A2—chronic kidney failure	0.027	0.0309	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC22A2—chronic kidney failure	0.0261	0.0299	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC22A2—chronic kidney failure	0.0232	0.0265	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Amine compound SLC transporters—SLC6A13—chronic kidney failure	0.0231	0.0265	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A13—chronic kidney failure	0.0224	0.0257	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—DDC—chronic kidney failure	0.0216	0.0248	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neurotransmitter Release Cycle—SLC22A2—chronic kidney failure	0.0206	0.0236	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC6A13—chronic kidney failure	0.0199	0.0228	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—ATXN2—chronic kidney failure	0.0192	0.022	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Amine compound SLC transporters—SLC22A2—chronic kidney failure	0.0181	0.0208	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neurotransmitter Release Cycle—SLC6A13—chronic kidney failure	0.0177	0.0202	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Amine compound SLC transporters—SLC22A2—chronic kidney failure	0.0161	0.0184	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Amine compound SLC transporters—SLC6A13—chronic kidney failure	0.0156	0.0178	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—nerve—chronic kidney failure	0.0139	0.145	CbGeAlD
Lisdexamfetamine—SLC18A2—blood plasma—chronic kidney failure	0.0139	0.145	CbGeAlD
Lisdexamfetamine—SLC6A3—Amine compound SLC transporters—SLC6A13—chronic kidney failure	0.0138	0.0158	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—ADIPOR1—chronic kidney failure	0.0137	0.0157	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—ADIPOR2—chronic kidney failure	0.0137	0.0157	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—DDC—chronic kidney failure	0.0129	0.0148	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—nerve—chronic kidney failure	0.0112	0.117	CbGeAlD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—DDC—chronic kidney failure	0.0107	0.0122	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A2—chronic kidney failure	0.0105	0.0121	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A13—chronic kidney failure	0.00904	0.0104	CbGpPWpGaD
Lisdexamfetamine—Lisinopril—ACE—chronic kidney failure	0.00886	0.28	CrCbGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—NOS1—chronic kidney failure	0.00771	0.00883	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A2—chronic kidney failure	0.00709	0.00812	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—NOS1—chronic kidney failure	0.00683	0.00782	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—renal system—chronic kidney failure	0.00656	0.0688	CbGeAlD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—DRD1—chronic kidney failure	0.00651	0.00746	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—kidney—chronic kidney failure	0.00634	0.0665	CbGeAlD
Lisdexamfetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A2—chronic kidney failure	0.00628	0.0072	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A13—chronic kidney failure	0.00609	0.00697	CbGpPWpGaD
Lisdexamfetamine—Selegiline—CYP2B6—chronic kidney failure	0.00607	0.192	CrCbGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—PRKD1—chronic kidney failure	0.00595	0.00681	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—SLC22A2—chronic kidney failure	0.00591	0.00677	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC34A1—chronic kidney failure	0.00563	0.00645	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PRKAG2—chronic kidney failure	0.0056	0.00641	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—DRD1—chronic kidney failure	0.00547	0.00627	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A13—chronic kidney failure	0.00539	0.00617	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—digestive system—chronic kidney failure	0.00533	0.0559	CbGeAlD
Lisdexamfetamine—SLC18A2—blood—chronic kidney failure	0.00507	0.0533	CbGeAlD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A13—chronic kidney failure	0.00507	0.00581	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC22A2—chronic kidney failure	0.00479	0.00549	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC7A9—chronic kidney failure	0.00467	0.00535	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—SLC22A2—chronic kidney failure	0.00453	0.00519	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC6A13—chronic kidney failure	0.00439	0.00503	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—CPT1A—chronic kidney failure	0.00413	0.00473	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A13—chronic kidney failure	0.00411	0.00471	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—KEAP1—chronic kidney failure	0.00398	0.00456	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC6A13—chronic kidney failure	0.00389	0.00445	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—SLC6A13—chronic kidney failure	0.00388	0.00445	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—TGFB1—chronic kidney failure	0.00382	0.00438	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—chronic kidney failure	0.00379	0.00434	CbGpPWpGaD
Lisdexamfetamine—Selegiline—CYP2C19—chronic kidney failure	0.00367	0.116	CrCbGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—SREBF1—chronic kidney failure	0.00361	0.00413	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—ABCC3—chronic kidney failure	0.0036	0.00413	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—gonad—chronic kidney failure	0.00355	0.0373	CbGeAlD
Lisdexamfetamine—SLC6A3—NRF2 pathway—KEAP1—chronic kidney failure	0.00353	0.00404	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—SLC22A2—chronic kidney failure	0.00352	0.00403	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—HMGCR—chronic kidney failure	0.00351	0.00402	CbGpPWpGaD
Lisdexamfetamine—Lisinopril—ABCB1—chronic kidney failure	0.00346	0.11	CrCbGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—ABCC2—chronic kidney failure	0.00345	0.00396	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—FASN—chronic kidney failure	0.00343	0.00393	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—GCKR—chronic kidney failure	0.00337	0.00387	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC34A1—chronic kidney failure	0.00336	0.00385	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—ADIPOQ—chronic kidney failure	0.00331	0.00379	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—HBEGF—chronic kidney failure	0.00326	0.00373	CbGpPWpGaD
Lisdexamfetamine—Phenelzine—CYP2C19—chronic kidney failure	0.00323	0.102	CrCbGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC22A2—chronic kidney failure	0.00322	0.00369	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—ABCC3—chronic kidney failure	0.00319	0.00366	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—IL1B—chronic kidney failure	0.00314	0.0036	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—chronic kidney failure	0.00314	0.0036	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—ABCC2—chronic kidney failure	0.00306	0.00351	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—PRKD1—chronic kidney failure	0.00302	0.00346	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—SLC6A13—chronic kidney failure	0.00302	0.00346	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC34A1—chronic kidney failure	0.00286	0.00328	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC22A2—chronic kidney failure	0.00286	0.00327	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—IL1B—chronic kidney failure	0.00278	0.00319	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC7A9—chronic kidney failure	0.00278	0.00319	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A13—chronic kidney failure	0.00277	0.00317	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—SLC22A2—chronic kidney failure	0.0027	0.00309	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC6A13—chronic kidney failure	0.00245	0.00281	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC22A2—chronic kidney failure	0.00243	0.00279	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC7A9—chronic kidney failure	0.00237	0.00272	CbGpPWpGaD
Lisdexamfetamine—Selegiline—CYP3A4—chronic kidney failure	0.00233	0.0738	CrCbGaD
Lisdexamfetamine—SLC6A3—Neuronal System—SLC6A13—chronic kidney failure	0.00232	0.00265	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TNF—chronic kidney failure	0.00228	0.00261	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—chronic kidney failure	0.00228	0.00261	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—GCKR—chronic kidney failure	0.00227	0.0026	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCG1—chronic kidney failure	0.00226	0.00259	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—HBEGF—chronic kidney failure	0.00218	0.0025	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A13—chronic kidney failure	0.00209	0.00239	CbGpPWpGaD
Lisdexamfetamine—Phenelzine—CYP3A4—chronic kidney failure	0.00205	0.065	CrCbGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TNF—chronic kidney failure	0.00202	0.00231	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—GCKR—chronic kidney failure	0.00201	0.0023	CbGpPWpGaD
Lisdexamfetamine—Selegiline—ABCB1—chronic kidney failure	0.00194	0.0614	CrCbGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—HBEGF—chronic kidney failure	0.00193	0.00221	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC34A1—chronic kidney failure	0.00193	0.00221	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—AVP—chronic kidney failure	0.00177	0.00203	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—OXT—chronic kidney failure	0.00175	0.002	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—GCKR—chronic kidney failure	0.00171	0.00196	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCC3—chronic kidney failure	0.00171	0.00196	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC34A1—chronic kidney failure	0.00171	0.00195	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—NPS—chronic kidney failure	0.00166	0.0019	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCC2—chronic kidney failure	0.00164	0.00188	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A2—chronic kidney failure	0.00164	0.00188	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC7A9—chronic kidney failure	0.0016	0.00183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—OXT—chronic kidney failure	0.00156	0.00179	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—RELA—chronic kidney failure	0.00154	0.00177	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCG1—chronic kidney failure	0.00152	0.00174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—chronic kidney failure	0.00148	0.0017	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A2—chronic kidney failure	0.00145	0.00166	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC7A9—chronic kidney failure	0.00141	0.00162	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A13—chronic kidney failure	0.00141	0.00161	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCG1—chronic kidney failure	0.00135	0.00154	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—NFKB1—chronic kidney failure	0.0013	0.00149	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD1—chronic kidney failure	0.00126	0.00144	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC6A13—chronic kidney failure	0.00124	0.00143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HBEGF—chronic kidney failure	0.00124	0.00142	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—NPY—chronic kidney failure	0.0012	0.00137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—AVP—chronic kidney failure	0.0012	0.00137	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—AVP—chronic kidney failure	0.00119	0.00137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—OXT—chronic kidney failure	0.00116	0.00133	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—GCKR—chronic kidney failure	0.00115	0.00132	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCC3—chronic kidney failure	0.00115	0.00132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CRHR1—chronic kidney failure	0.00115	0.00132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—EDN1—chronic kidney failure	0.00114	0.00131	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCC2—chronic kidney failure	0.00111	0.00127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—NPS—chronic kidney failure	0.0011	0.00126	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD1—chronic kidney failure	0.00108	0.00123	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—chronic kidney failure	0.00107	0.00123	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—chronic kidney failure	0.00107	0.00123	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—AVP—chronic kidney failure	0.00106	0.00121	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PTH—chronic kidney failure	0.00105	0.0012	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCC3—chronic kidney failure	0.00102	0.00117	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—GCKR—chronic kidney failure	0.00102	0.00117	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic kidney failure	0.00102	0.00117	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCC2—chronic kidney failure	0.00098	0.00112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—NPY—chronic kidney failure	0.000914	0.00105	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—AVP—chronic kidney failure	0.000901	0.00103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CRH—chronic kidney failure	0.000882	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—OXT—chronic kidney failure	0.000882	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—F2—chronic kidney failure	0.000874	0.001	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—chronic kidney failure	0.000872	0.000999	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—NPS—chronic kidney failure	0.000836	0.000957	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—DRD1—chronic kidney failure	0.00082	0.000939	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AVP—chronic kidney failure	0.000793	0.000909	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR5—chronic kidney failure	0.000787	0.000902	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—F2—chronic kidney failure	0.000782	0.000895	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic kidney failure	0.000755	0.000864	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL5—chronic kidney failure	0.000749	0.000858	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—PPARA—chronic kidney failure	0.000734	0.000841	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB1—chronic kidney failure	0.000725	0.000831	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—chronic kidney failure	0.000723	0.000828	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR5—chronic kidney failure	0.000675	0.000773	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CRHR1—chronic kidney failure	0.00065	0.000745	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB1—chronic kidney failure	0.000643	0.000736	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—chronic kidney failure	0.00064	0.000733	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—AVP—chronic kidney failure	0.000606	0.000694	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AVP—chronic kidney failure	0.000604	0.000692	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PTH—chronic kidney failure	0.000595	0.000681	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CRHR1—chronic kidney failure	0.00059	0.000676	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—chronic kidney failure	0.000587	0.000672	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—F2—chronic kidney failure	0.000579	0.000663	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—EDN1—chronic kidney failure	0.000575	0.000658	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCL5—chronic kidney failure	0.00057	0.000653	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ALB—chronic kidney failure	0.000546	0.000625	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTH—chronic kidney failure	0.00054	0.000618	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—AVP—chronic kidney failure	0.000537	0.000615	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—chronic kidney failure	0.000527	0.000604	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—chronic kidney failure	0.00052	0.000596	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—NPY—chronic kidney failure	0.000516	0.000591	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—chronic kidney failure	0.000516	0.000591	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCR5—chronic kidney failure	0.000514	0.000588	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—OXT—chronic kidney failure	0.000498	0.000571	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CRH—chronic kidney failure	0.000498	0.000571	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—COL4A5—chronic kidney failure	0.000495	0.000567	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PPARA—chronic kidney failure	0.000494	0.000566	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—NPS—chronic kidney failure	0.000472	0.000541	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NPY—chronic kidney failure	0.000469	0.000537	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD1—chronic kidney failure	0.000463	0.000531	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TFDP2—chronic kidney failure	0.00046	0.000527	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—OXT—chronic kidney failure	0.000452	0.000518	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CRH—chronic kidney failure	0.000452	0.000518	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIP5K1B—chronic kidney failure	0.00045	0.000516	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—F2—chronic kidney failure	0.000441	0.000505	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PPARA—chronic kidney failure	0.000438	0.000501	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NPS—chronic kidney failure	0.000429	0.000491	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD1—chronic kidney failure	0.000421	0.000482	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PGF—chronic kidney failure	0.00041	0.00047	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—POMC—chronic kidney failure	0.000402	0.00046	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCL2—chronic kidney failure	0.000393	0.00045	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKAG2—chronic kidney failure	0.000386	0.000442	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—chronic kidney failure	0.00038	0.000436	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic kidney failure	0.000367	0.000421	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—COL4A3—chronic kidney failure	0.000366	0.000419	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HBEGF—chronic kidney failure	0.000358	0.00041	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CRHR1—chronic kidney failure	0.000349	0.000399	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AVP—chronic kidney failure	0.000341	0.000391	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LRP2—chronic kidney failure	0.000334	0.000383	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ALB—chronic kidney failure	0.000325	0.000373	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—EDN1—chronic kidney failure	0.000325	0.000372	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCL5—chronic kidney failure	0.000322	0.000369	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTH—chronic kidney failure	0.000319	0.000365	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CYBB—chronic kidney failure	0.000311	0.000356	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AVP—chronic kidney failure	0.00031	0.000355	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic kidney failure	0.000309	0.000354	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EDN1—chronic kidney failure	0.000295	0.000338	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF23—chronic kidney failure	0.000294	0.000337	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL5—chronic kidney failure	0.000293	0.000335	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR5—chronic kidney failure	0.00029	0.000333	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPY—chronic kidney failure	0.000277	0.000317	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CRH—chronic kidney failure	0.000267	0.000306	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—OXT—chronic kidney failure	0.000267	0.000306	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR5—chronic kidney failure	0.000264	0.000302	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NCF1—chronic kidney failure	0.000256	0.000293	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPS—chronic kidney failure	0.000253	0.00029	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—F2—chronic kidney failure	0.000249	0.000285	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD1—chronic kidney failure	0.000248	0.000285	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CYBA—chronic kidney failure	0.000241	0.000276	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—POMC—chronic kidney failure	0.000227	0.00026	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—F2—chronic kidney failure	0.000226	0.000259	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HBEGF—chronic kidney failure	0.000211	0.000242	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—POMC—chronic kidney failure	0.000206	0.000236	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL2—chronic kidney failure	0.000202	0.000231	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AVP—chronic kidney failure	0.000183	0.00021	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EDN1—chronic kidney failure	0.000174	0.0002	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL5—chronic kidney failure	0.000173	0.000198	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LPL—chronic kidney failure	0.000169	0.000194	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NGF—chronic kidney failure	0.00016	0.000183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR5—chronic kidney failure	0.000156	0.000178	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—F2—chronic kidney failure	0.000134	0.000153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IRS1—chronic kidney failure	0.000126	0.000145	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—POMC—chronic kidney failure	0.000122	0.000139	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL2—chronic kidney failure	0.000119	0.000136	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1—chronic kidney failure	0.000117	0.000134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SERPINE1—chronic kidney failure	0.000111	0.000127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—chronic kidney failure	0.00011	0.000126	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOS3—chronic kidney failure	0.000106	0.000122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RELA—chronic kidney failure	9.99e-05	0.000114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—chronic kidney failure	8.95e-05	0.000103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NFKB1—chronic kidney failure	8.43e-05	9.65e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—chronic kidney failure	7.65e-05	8.76e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFB1—chronic kidney failure	7.02e-05	8.04e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—chronic kidney failure	6.5e-05	7.45e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—chronic kidney failure	5.29e-05	6.06e-05	CbGpPWpGaD
